Bluepharma Industria Farmaceutica S.A.
17
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 17 trials
0%
0 trials in Phase 3/4
0%
6 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
Role: lead
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
Role: lead
Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions
Role: lead
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Role: lead
Bioequivalence of Eltrombopag 25 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Role: lead
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects
Role: lead
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Role: lead
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules in Healthy Subjects.
Role: lead
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Role: lead
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions
Role: lead
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions.
Role: lead
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
Role: lead
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
Role: lead
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions
Role: lead
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions.
Role: lead
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.
Role: lead
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Role: lead
All 17 trials loaded